O	0	1	A
O	2	7	phase
O	8	10	II
O	11	21	randomized
O	22	30	clinical
O	31	36	trial
O	37	39	of
O	40	43	the
O	44	50	effect
O	51	53	of
B-intervention	54	63	metformin
O	64	70	versus
B-control	71	78	placebo
O	79	81	on
O	82	93	progression
O	93	94	-
O	94	98	free
O	99	107	survival
O	108	110	in
O	111	116	women
O	117	121	with
O	122	132	metastatic
O	133	139	breast
O	140	146	cancer
O	147	156	receiving
O	157	165	standard
O	166	178	chemotherapy
O	178	179	.

O	180	183	Pre
O	183	184	-
O	184	192	clinical
O	193	197	data
O	198	205	suggest
O	206	215	metformin
O	216	221	might
O	222	229	enhance
O	230	233	the
O	234	240	effect
O	241	243	of
O	244	256	chemotherapy
O	257	259	in
O	260	266	breast
O	267	273	cancer
O	274	275	(
O	275	277	BC
O	277	278	)
O	278	279	.

O	280	282	We
O	283	292	conducted
O	293	294	a
O	295	300	Phase
O	301	303	II
O	304	314	randomized
O	315	320	trial
O	321	323	of
O	324	336	chemotherapy
O	337	341	plus
O	342	351	metformin
O	352	358	versus
O	359	366	placebo
O	367	369	in
O	370	380	metastatic
O	381	387	breast
O	388	394	cancer
O	395	396	(
O	396	399	MBC
O	399	400	)
O	400	401	.

O	402	404	In
O	405	409	this
O	410	416	double
O	417	422	blind
O	423	428	phase
O	429	431	II
O	432	437	trial
O	438	440	we
O	441	449	randomly
O	450	458	assigned
B-eligibility	459	462	non
I-eligibility	462	463	-
I-eligibility	463	471	diabetic
I-eligibility	472	475	MBC
I-eligibility	476	484	patients
I-eligibility	485	487	on
I-eligibility	488	491	1st
I-eligibility	492	494	to
I-eligibility	495	498	4th
I-eligibility	499	503	line
I-eligibility	504	516	chemotherapy
O	517	519	to
O	520	527	receive
O	528	537	metformin
O	538	541	850
O	542	544	mg
O	545	547	po
O	548	551	bid
O	552	554	or
O	555	562	placebo
O	563	566	bid
O	566	567	.

O	568	575	Primary
O	576	583	outcome
O	584	587	was
B-outcome-Measure	588	599	progression
I-outcome-Measure	599	600	-
I-outcome-Measure	600	604	free
I-outcome-Measure	605	613	survival
I-outcome-Measure	614	615	(
I-outcome-Measure	615	618	PFS
I-outcome-Measure	618	619	)
O	619	620	;
O	621	630	secondary
O	631	639	outcomes
O	640	648	included
B-outcome-Measure	649	656	overall
I-outcome-Measure	657	665	survival
I-outcome-Measure	666	667	(
I-outcome-Measure	667	669	OS
I-outcome-Measure	669	670	)
O	670	671	,
B-outcome-Measure	672	680	response
I-outcome-Measure	681	685	rate
I-outcome-Measure	686	687	(
I-outcome-Measure	687	689	RR
I-outcome-Measure	689	690	)
O	690	691	,
B-outcome-Measure	692	700	toxicity
O	701	704	and
B-outcome-Measure	705	712	quality
I-outcome-Measure	713	715	of
I-outcome-Measure	716	720	life
I-outcome-Measure	721	722	(
I-outcome-Measure	722	725	QOL
I-outcome-Measure	725	726	)
O	726	727	.

O	728	732	With
B-total-participants	733	735	40
O	736	744	subjects
O	745	748	and
O	749	750	a
O	751	755	type
O	755	756	-
O	756	759	one
O	760	765	error
O	766	768	of
O	769	770	0
O	770	771	.
O	771	772	2
O	773	774	(
O	774	777	one
O	777	778	-
O	778	783	sided
O	783	784	)
O	784	785	,
O	786	787	a
B-outcome	788	791	PFS
O	792	798	hazard
O	799	804	ratio
O	805	806	(
O	806	808	HR
O	808	809	)
O	810	812	of
O	813	814	0
O	814	815	.
O	815	817	58
O	818	823	could
O	824	826	be
O	827	835	detected
O	836	840	with
O	841	843	80
O	843	844	%
O	845	850	power
O	850	851	.

B-total-participants	852	854	40
O	855	863	patients
O	864	868	were
O	869	879	randomized
O	880	881	(
B-intervention-participants	881	883	22
O	884	893	metformin
O	893	894	,
B-control-participants	895	897	18
O	898	905	placebo
O	905	906	)
O	907	911	with
O	912	913	a
O	914	918	mean
O	919	922	age
O	923	925	of
B-age	926	928	55
I-age	929	931	vs
I-age	932	934	57
I-age	935	940	years
O	941	944	and
O	945	947	ER
O	947	948	/
O	948	950	PR
O	951	959	positive
O	960	962	BC
O	963	965	in
O	966	968	86
O	968	969	.
O	969	970	4
O	970	971	%
O	972	974	vs
O	975	977	83
O	977	978	.
O	978	979	3
O	979	980	%
O	981	984	off
O	985	994	metformin
O	995	997	vs
O	998	1005	placebo
O	1005	1006	,
O	1007	1019	respectively
O	1019	1020	.

O	1021	1025	Mean
O	1026	1029	BMI
O	1030	1033	was
O	1034	1038	27kg
O	1038	1039	/
O	1039	1041	m2
O	1042	1044	in
O	1045	1049	both
O	1050	1054	arms
O	1054	1055	.

O	1056	1059	The
O	1060	1068	majority
O	1069	1071	of
O	1072	1080	patients
O	1081	1085	were
O	1086	1088	on
O	1089	1092	1st
O	1093	1097	line
O	1098	1110	chemotherapy
O	1110	1111	.

B-outcome	1112	1117	Grade
I-outcome	1118	1119	3
I-outcome	1119	1120	-
I-outcome	1120	1121	4
I-outcome	1122	1130	toxicity
O	1131	1139	occurred
O	1140	1142	in
B-iv-bin-percent	1143	1145	31
I-iv-bin-percent	1145	1146	.
I-iv-bin-percent	1146	1147	8
I-iv-bin-percent	1147	1148	%
O	1149	1150	(
O	1150	1159	metformin
O	1159	1160	)
O	1161	1163	vs
B-cv-bin-percent	1164	1166	58
I-cv-bin-percent	1166	1167	.
I-cv-bin-percent	1167	1168	8
I-cv-bin-percent	1168	1169	%
O	1170	1171	(
O	1171	1178	placebo
O	1178	1179	)
O	1179	1180	.

O	1181	1185	Best
O	1186	1194	response
O	1194	1195	:
B-outcome	1196	1203	Partial
I-outcome	1204	1212	response
B-iv-bin-percent	1213	1215	18
I-iv-bin-percent	1215	1216	.
I-iv-bin-percent	1216	1217	2
I-iv-bin-percent	1217	1218	%
O	1219	1228	metformin
O	1229	1231	vs
B-cv-bin-percent	1232	1234	25
I-cv-bin-percent	1234	1235	%
O	1236	1243	placebo
O	1243	1244	,
B-outcome	1245	1251	stable
I-outcome	1252	1259	disease
B-iv-bin-percent	1260	1262	36
I-iv-bin-percent	1262	1263	.
I-iv-bin-percent	1263	1264	4
I-iv-bin-percent	1264	1265	%
O	1266	1275	metformin
O	1276	1278	vs
B-cv-bin-percent	1279	1281	18
I-cv-bin-percent	1281	1282	.
I-cv-bin-percent	1282	1283	8
I-cv-bin-percent	1283	1284	%
O	1285	1292	placebo
O	1292	1293	,
B-outcome	1294	1305	progressive
I-outcome	1306	1313	disease
B-iv-bin-percent	1314	1316	45
I-iv-bin-percent	1316	1317	.
I-iv-bin-percent	1317	1318	4
I-iv-bin-percent	1318	1319	%
O	1320	1329	metformin
O	1330	1332	vs
B-cv-bin-percent	1333	1335	56
I-cv-bin-percent	1335	1336	.
I-cv-bin-percent	1336	1337	2
I-cv-bin-percent	1337	1338	%
O	1339	1346	placebo
O	1346	1347	.

B-outcome	1348	1352	Mean
I-outcome	1353	1356	PFS
O	1357	1360	was
B-iv-cont-mean	1361	1362	5
I-iv-cont-mean	1362	1363	.
I-iv-cont-mean	1363	1364	4
O	1365	1367	vs
B-cv-cont-mean	1368	1369	6
I-cv-cont-mean	1369	1370	.
I-cv-cont-mean	1370	1371	3
I-cv-cont-mean	1372	1378	months
O	1379	1380	(
O	1380	1389	metformin
O	1390	1392	vs
O	1393	1400	placebo
O	1400	1401	)
O	1401	1402	,
O	1403	1405	HR
O	1406	1407	1
O	1407	1408	.
O	1408	1409	2
O	1410	1411	(
O	1411	1413	95
O	1413	1414	%
O	1415	1417	CI
O	1418	1419	0
O	1419	1420	.
O	1420	1422	63
O	1422	1423	-
O	1423	1424	2
O	1424	1425	.
O	1425	1427	31
O	1427	1428	)
O	1428	1429	.

B-outcome	1430	1434	Mean
I-outcome	1435	1437	OS
O	1438	1441	was
B-iv-cont-mean	1442	1444	20
I-iv-cont-mean	1444	1445	.
I-iv-cont-mean	1445	1446	2
O	1447	1448	(
O	1448	1457	metformin
O	1457	1458	)
O	1459	1461	vs
B-cv-cont-mean	1462	1464	24
I-cv-cont-mean	1464	1465	.
I-cv-cont-mean	1465	1466	2
I-cv-cont-mean	1467	1473	months
O	1474	1475	(
O	1475	1482	placebo
O	1482	1483	)
O	1483	1484	,
O	1485	1487	HR
O	1488	1489	1
O	1489	1490	.
O	1490	1492	68
O	1493	1494	(
O	1494	1496	95
O	1496	1497	%
O	1498	1500	CI
O	1501	1502	0
O	1502	1503	.
O	1503	1505	79
O	1505	1506	-
O	1506	1507	3
O	1507	1508	.
O	1508	1510	55
O	1510	1511	)
O	1511	1512	.

O	1513	1515	In
O	1516	1520	this
O	1521	1531	population
O	1532	1541	metformin
O	1542	1548	showed
O	1549	1551	no
O	1552	1563	significant
O	1564	1570	effect
O	1571	1573	on
B-outcome	1574	1576	RR
O	1576	1577	,
B-outcome	1578	1581	PFS
O	1582	1584	or
B-outcome	1585	1587	OS
O	1587	1588	.

O	1589	1594	These
O	1595	1602	results
O	1603	1605	do
O	1606	1609	not
O	1610	1617	support
O	1618	1621	the
O	1622	1625	use
O	1626	1628	of
O	1629	1638	metformin
O	1639	1643	with
O	1644	1656	chemotherapy
O	1657	1659	in
O	1660	1663	non
O	1663	1664	-
O	1664	1672	diabetic
O	1673	1676	MBC
O	1677	1685	patients
O	1685	1686	.
